Swiss cardiac stent maker Biosensors International will pay at least $51 million for U.S.-based Spectrum Dynamics, a developer of high-definition medical imaging technology.
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.
Biodesix reeled in another $8.8 million in financing toward expanding sales and marketing for VeriStrat, its molecular diagnostic blood test to help guide treatment for patients with advanced non-small cell lung cancer. The new funding will also propel further research work involving the technology.
Blood test versus a tumor biopsy: Which reveals more gene mutations in the diagnostics and treatment of gastrointestinal cancer? New research from Dana-Farber Cancer Institute in Boston points very much to the former.
In a small study mounted at the University of Pennsylvania, a novel combination approach using a personalized therapeutic vaccine made from dendritic cells primed with a patient's tumor cells was successfully used to fight advanced ovarian cancer.
Academia is increasingly realizing the medical and financial possibilities that building persona lized medicine programs can bring. Case in point: The Perelman School of Medicine at the University of Pennsylvania this year has unveiled the Center for Personalized Diagnostics, a joint initiative from the school's department of Pathology and Laboratory medicine and the Abramson Cancer Center.
Analysts predict enormous gains in the nanotechnology drug delivery market for the next three years, according to a new report. But the good news comes with a hovering rain cloud, as safety concerns regarding nanomedicines may dampen a bright future.
A new genomics upstart has taken flight to create a new way of mobilizing personal DNA data. Miinome aims to offer a unique personal genetic marketplace, serving as a broker between peoples' genetic info and buyers of the data.
The U.K.'s National Health Service is propelling its diagnostic offerings deeper into the realm of personalized medicine. It will offer a new test that spots mutations in 46 different cancer cell genes in order to gauge how a patient will respond to treatment.
Scientists at the University of Nottingham in the U.K. are developing a quick blood test for early-stage Alzheimer's. The goal, according to a BBC story on the finding, is a diagnostic that would enable earlier intervention, as well as a personalized drug treatment.